Valuation: vTv Therapeutics Inc.

Market Cap 390M 340M 321M 291M 545M 37.4B 548M 3.83B 1.48B 19.02B 1.47B 1.43B 61.19B P/E 2026 *
-14.9x
P/E 2027 * -7.75x
Enterprise Value 390M 340M 321M 291M 545M 37.4B 548M 3.83B 1.48B 19.02B 1.47B 1.43B 61.19B EV / Sales 2026 *
14x
EV / Sales 2027 * -
Free-Float
61.17%
Yield 2026 *
-
Yield 2027 * -
1 day+1.27%
1 week-0.19%
Current month-0.62%
1 month+1.56%
3 months-6.25%
6 months-13.35%
Current year-20.48%
1 week 29.76
Extreme 29.76
32.53
1 month 29.76
Extreme 29.76
34.76
Current year 28.75
Extreme 28.75
44
1 year 19.5
Extreme 19.5
44
3 years 7.38
Extreme 7.38
44
5 years 7.38
Extreme 7.38
86.8
10 years 7.38
Extreme 7.38
336
Manager TitleAgeSince
Chief Executive Officer 68 2022-07-31
Director of Finance/CFO 50 2025-05-18
Chief Tech/Sci/R&D Officer - 2023-11-01
Director TitleAgeSince
Director/Board Member 56 2020-11-15
Director/Board Member 48 2022-07-10
Chairman 68 2024-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/26/26 Free

Director

6,000 0.1523%
2/17/26 Free

Chief Financial Officer

44,969 1.1419%
2/17/26 Free

Chief Executive Officer

140,000 3.5551%
Change 5-day change 1-year change 3-year change Capi.($)
+1.27%-0.19%+51.22%+78.61% 390M
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-5.72%-17.12%+350.96% 27.07B
-2.64%-0.35%-2.13%-15.04% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+1.62%+44.31%+167.58% 14.49B
+0.73%+5.00%-1.33%+854.55% 14.14B
-0.54%-0.30%+27.33%+202.19% 12.35B
Average -0.40%+1.37%+38.61%+209.23% 26.26B
Weighted average by Cap. -0.53%+1.38%+35.81%+161.22%

Financials

2026 *2027 *
Net sales 27.9M 24.29M 22.93M 20.83M 39.01M 2.67B 39.2M 274M 106M 1.36B 105M 102M 4.38B -
Net income -26.7M -23.24M -21.94M -19.93M -37.33M -2.56B -37.51M -262M -101M -1.3B -100M -98.05M -4.19B -63.19M -55.01M -51.93M -47.18M -88.35M -6.06B -88.78M -621M -240M -3.08B -237M -232M -9.91B
Net Debt - -
Logo vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Employees
26
Date Price Change Volume
26-09-18 US$31.80 +1.27% 72,834
26-09-17 US$31.40 +3.09% 33,385
26-09-16 US$30.46 0.00% 91,475
26-09-15 US$30.46 -3.12% 45,335
26-09-14 US$31.44 -1.66% 22,151
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
31.80USD
Average target price
54.71USD
Spread / Average Target
+72.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VTVT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!